Chemical Structure (Des Structure)
Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-1753
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-1753). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Figure 1)
The text is a table presenting PK (Pharmacokinetic) geometric mean ratios with 90% confidence intervals for different conditions such as renal impairment, hepatic impairment, gender, and age. It shows the relative change in the maximum concentration (Cmax) and the Area Under the Curve (AUC) for specific patient groups compared to a reference. The table indicates that the ratio's range differs depending on the severity of the condition. The reference values are not provided. ESRD stands for End Stage Renal Disease.*
Figure 2 (Figure 2)
This is a description of a study or experiment involving the effects of CYP3A4 inhibitors, specifically the drug Ketoconazole, on the body's ability to process certain substances. The text includes measurements of geometric mean ratios and changes relative to a reference, suggesting data analysis. However, without more context, the purpose and implications of the study cannot be determined.*
Figure 3 (Figure 3)
Figure 4 (Figure 4)
This graph depicts the estimated proportion of patients with relapse over time in days (x-axis) after receiving Desvenlafaxine Extended-Release Tablets 50mg or Placebo. The y-axis shows the estimated proportion of patients with relapse in percentages. The graph indicates that after 150 days from randomization, approximately 50% of patients receiving Desvenlafaxine Extended-Release Tablets 50mg experienced relapse compared to 40% on Placebo.*
Figure 5 (Figure 5)
This appears to be a graph or chart displaying the estimated proportion of patients with relapse over time from randomization. The X-axis shows the time to relapse in days, and the Y-axis shows the estimated proportion of patients with relapse. The graph compares Desvenlafaxine Extended-Release Tablets to a placebo, with a vertical line separating the two. However, without additional information or context, the graph may not be entirely useful on its own.*
Label (Lbl713351753)
This is a package label for a medication called Pristiq 50mg Tablet, packaged by Bryant Ranck Prepack. It includes information such as the manufacturer, quantity (30 tablets), expiration date (not specified), NDC number, and storage instructions. The label also includes a caution to keep all drugs out of the reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
